Want to see CAH full AI Analyst Report?
Profit Margin by Segment
Reveals the profitability ratio for each business segment, indicating how well each unit converts revenue into profit and where efficiency improvements can be made.Margins are bifurcating: Pharmaceutical profitability has been steadier and is trending higher recently, which supports management’s decision to raise Pharma profit guidance and underpins the upgraded EPS outlook; by contrast the Medical/GMPD margin is far more volatile and has softened materially year‑over‑year, consistent with tariff pressure, IRA/WAC mix headwinds and GLP‑1 moderation noted on the call. That divergence means upside is likely tied to Pharma and Other growth businesses, while Medical creates a lumpier, policy‑sensitive downside risk to near‑term earnings.
Date | Pharmaceutical | Medical |
|---|---|---|
Jun 30, 2026 | 1.10 | 4.80 |
Mar 31, 2026 | 1.40 | 0.79 |
Dec 31, 2025 | 1.10 | 1.07 |
Sep 30, 2025 | 1.13 | 1.44 |
Jun 30, 2025 | 0.96 | 2.20 |
Mar 31, 2025 | 1.31 | 1.23 |
Dec 31, 2024 | 1.04 | 0.56 |
Sep 30, 2024 | 1.10 | 0.26 |
Jun 30, 2024 | 0.87 | 1.51 |
Mar 31, 2024 | 1.15 | 0.64 |